Therefore, these results suggested that IL-6 induced JAK2/STAT3 pathway was associated with survival and metastasis in RCC cells, and inhibition of IL-6 induced JAK2/STAT3 signaling pathway could sensitize RCC cells to simvastatin treatment. The gene discussed is JAK2; the disease is renal cell carcinoma.